The most important human pathogen Streptococcus pyogenes shares an intimate evolutionary historical past with cellular genetic parts, which in lots of circumstances carry genes encoding bacterial virulence elements. Throughout current whole-genome sequencing of a longitudinal pattern of S. pyogenes isolates in England, we recognized a lineage inside emmemmemmemmS. pyogenes appeared to represent predominantly MEW427-like isolates, whereas the UK inhabitants comprised each MEW427-like and MGAS10750-like isolates.
The degraded and cryptic nature of those parts might have necessary phenotypic and health ramifications for emmS. pyogenes, and the geographical distribution of this lineage raises fascinating questions on the inhabitants dynamics of the genotype.
Sequential quadriplex real-time PCR for figuring out 20 frequent emm varieties of Group A Streptococcus
We developed a sequential quadriplex real-time PCR-based methodology for fast identification of 20 emm sorts generally present in invasive GAS (iGAS) strains recovered by means of the Facilities for Illness Management and Prevention’s Lively Bacterial Core surveillance.
Every emm real-time PCR assay exhibits excessive specificity and precisely recognized the respective goal emm kind, together with emm subtypes in the US. Moreover, this methodology is helpful for fast typing of GAS isolates and culture-negative specimens throughout outbreak investigations.
Development inhibition of pathogenic microorganisms by Pseudomonas protegens EMM-1 and partial characterization of inhibitory substances
The bacterial pressure, EMM-1, was remoted from the rhizosphere of purple maize (“Rojo Criollo”) and recognized as Pseudomonas protegens EMM-1 primarily based on phylogenetic evaluation of 16S rDNA, rpoB, rpoD, and gyrB gene sequences. We uncovered genes concerned within the manufacturing of antimicrobial compounds like 2,4-diacetylphloroglucinol (2,4-DAPG), pyoluteorin, and lectin-like bacteriocins.
These antimicrobial compounds are additionally produced by different fluorescent pseudomonads alike P. protegens. Double-layer agar assay confirmed that P. protegens EMM-1 inhibited the expansion of a number of multidrug-resistant (MDR) micro organism, particularly scientific isolates of the genera Klebsiella and β-hemolytic Streptococcus.
This pressure additionally displayed inhibitory results towards various fungi, resembling Aspergillus, Botrytis, and Fusarium. In addition to, a crude extract of inhibitory substances secreted into agar was obtained after the cold-leaching course of, and physicochemical characterization was carried out. The partially purified inhibitory substances produced by P. protegens EMM-1 inhibited the expansion of Streptococcus sp. and Microbacterium sp., however no inhibitory impact was famous for different bacterial or fungal strains.
The molecular weight decided after ultrafiltration was between Three and 10 kDa. The inhibitory exercise was thermally secure as much as 60°C (however utterly misplaced at 100°C), and the inhibitory exercise remained energetic in a large pH vary (from Three to 9). After therapy with a protease from Bacillus licheniformis, the inhibitory exercise was decreased by 90%, suggesting the presence of proteic pure compounds. All these findings prompt that P. protegens EMM-1 is a possible supply of antimicrobials for use towards pathogens for people and crops.
Systematic Evaluate and Meta-analysis of the Prevalence of Group A Streptococcal emm Clusters in Africa To Inform Vaccine Growth
An emm-cluster primarily based system was proposed as a regular typing scheme to facilitate and improve future research of group A Streptococcus (GAS) epidemiological surveillance, M protein operate, and vaccine improvement methods. We offer an evidence-based distribution of GAS emm clusters in Africa and assess the potential protection of the brand new 30-valent vaccine by way of an emm cluster-based method.
Two reviewers independently assessed research retrieved from a complete search and extracted related knowledge. Meta-analyses had been carried out (random-effects mannequin) to mixture emm cluster prevalence estimates. Eight research (n = 1,595 isolates) revealed the predominant emm clusters as E6 (18%; 95% confidence interval [CI], 12.6% to 24.0%), adopted by E3 (14%; 95% CI, 11.2% to 17.4%) and E4 (13%; 95% CI, 9.5% to 16.0%).
There was negligible variation in emm clusters with regard to areas, age, and socioeconomic standing throughout the continent. Contemplating an emm cluster-based vaccine technique, which assumes cross-protection inside clusters, the 30-valent vaccine presently in scientific improvement would supply hypothetical protection to 80.3% of isolates in Africa.
This systematic evaluation signifies essentially the most predominant GAS emm cluster in Africa is E6 adopted by E3, E4, and D4. The present 30-valent vaccine would supply appreciable protection throughout the range of emm cluster sorts in Africa. Future efforts could possibly be directed towards estimating the general potential protection of the brand new 30-valent vaccine primarily based on cross-opsonization research with consultant panels of GAS isolates from populations at highest danger for GAS ailments.
IMPORTANCE Low vaccine protection is of grave public well being concern, notably in growing nations the place epidemiological knowledge are sometimes absent. To tell vaccine improvement for group A Streptococcus (GAS), we report on the epidemiology of the M protein emm clusters from GAS infections in Africa, the place GAS-related sicknesses and their sequelae, together with rheumatic fever and rheumatic coronary heart illness, are of a excessive burden.
This primary report of emm clusters throughout the continent signifies a excessive in all probability of protection by the M protein-based vaccine presently present process testing had been an emm-cluster primarily based method for use.
emm Varieties and clusters and macrolide resistance of pediatric group A streptococcal isolates in Central Greece throughout 2011-2017.
The surveillance of emm sorts and macrolide susceptibility of group A streptococcus (GAS) in varied areas and time durations enhances the understanding of the epidemiology of GAS infections and should information therapy methods and the formulation of type-specific vaccines. Greece has emerged as a rustic with excessive macrolide use. Nonetheless, research counsel a gradual discount in macrolide consumption after 2007.
Throughout a 7-year interval (2011-2017), 604 GAS isolates had been recovered from consecutive kids presenting with pharyngeal or nonpharyngeal infections in Central Greece; 517 viable isolates underwent molecular evaluation, together with emm typing.Isolates belonged to 20 completely different emm sorts (in lowering order of prevalence: 1, 89, 4, 12, 28, 3, 75 and 6, accounting for 88.2% of complete isolates). The emm sorts comprised 10 emm clusters (5 commonest clusters: E4, A-C3, E1, A-C4 and A-C5). The emm89 isolates had been acapsular (‘new clade’).
Total macrolide resistance price was 15.4%, and cMLSB emerged because the predominant resistance phenotype (56.4%). The bottom annual resistance charges occurred in 2014 (13.1%), 2016 (5.5%) and 2017(8.0%) (P for development = 0.002). Consumption of macrolide/lincosamide/streptogramin B declined by 22.6% throughout 2011-2017.
Macrolide resistance and emm28 and emm77 sorts had been related (each P<0.001). Essentially the most steadily recognized genetic lineages of macrolide-resistant GAS included emm28/ST52, emm77/ST63, emm12/ST36, emm89/ST101 and emm4/ST39. We estimated that 98.8% of the isolates belonged to emm sorts integrated right into a novel 30-valent M protein vaccine.In Central Greece throughout 2011-2017, the acapsular emm89 isolates comprised the second most prevalent kind.
Mouse Monoclonal Anti-Human CD147, Unlabeled |
|||
| CD147UL-100 | Alpha Diagnostics | 100 ug | 489.6 EUR |
Anti-Hu CD147 PE |
|||
| 1P-274-T025 | ExBio | 25 tests | 168 EUR |
Anti-Hu CD147 PE |
|||
| 1P-274-T100 | ExBio | 100 tests | 288 EUR |
Anti-Hu CD147 Purified |
|||
| 11-274-C025 | ExBio | 0.025 mg | 124.8 EUR |
Anti-Hu CD147 Purified |
|||
| 11-274-C100 | ExBio | 0.1 mg | 200.4 EUR |
Anti-Hu CD147 Purified |
|||
| 11-454-C025 | ExBio | 0.025 mg | 124.8 EUR |
Anti-Hu CD147 Purified |
|||
| 11-454-C100 | ExBio | 0.1 mg | 200.4 EUR |
Anti-Hu CD147 APC |
|||
| 1A-274-T025 | ExBio | 25 tests | 168 EUR |
Anti-Hu CD147 APC |
|||
| 1A-274-T100 | ExBio | 100 tests | 288 EUR |
Anti-Hu CD147 Biotin |
|||
| 1B-274-C025 | ExBio | 0.025 mg | 146.4 EUR |
Anti-Hu CD147 Biotin |
|||
| 1B-274-C100 | ExBio | 0.1 mg | 244.8 EUR |
Anti-Hu CD147 FITC |
|||
| 1F-274-T025 | ExBio | 25 tests | 146.4 EUR |
Anti-Hu CD147 FITC |
|||
| 1F-274-T100 | ExBio | 100 tests | 244.8 EUR |
Anti-CD147/BSG Antibody |
|||
| PA1526 | BosterBio | 100ug/vial | 352.8 EUR |
Anti-CD147/BSG Antibody |
|||
| PB9247 | BosterBio | 100ug/vial | 400.8 EUR |
CD147 |
|||
| 147A1-100T | ImmunoStep | 100 test | 418.8 EUR |
CD147 |
|||
| 147CFB1-100T | ImmunoStep | 100 test | 465.6 EUR |
CD147 |
|||
| 147F1-100T | ImmunoStep | 100 test | 356.4 EUR |
CD147 |
|||
| 147P1E-100T | ImmunoStep | 100 test | 418.8 EUR |
CD147 |
|||
| 147PE2-100T | ImmunoStep | 100 test | 418.8 EUR |
CD147 |
|||
| 147PP1-100T | ImmunoStep | 100 test | 418.8 EUR |
CD147 |
|||
| 147PU1-01MG | ImmunoStep | 0,1 mg | 262.8 EUR |
Mouse Anti Human Cd147 Monoclonal Antibody,RPE |
|||
| CABT-47077MH | Creative Diagnostics | 100 TEST | 852 EUR |
Rat Anti Mouse Cd147 Monoclonal Antibody,Biotin |
|||
| CABT-47085RM | Creative Diagnostics | 0.1 mg | 514.8 EUR |
Rat Anti Mouse Cd147 Monoclonal Antibody,FITC |
|||
| CABT-47088RM | Creative Diagnostics | 0.1 mg | 546 EUR |
Rat Anti Mouse Cd147 Monoclonal Antibody,RPE |
|||
| CABT-47093RM | Creative Diagnostics | 100 TEST | 639.6 EUR |
Mouse Anti Rat Cd147 Monoclonal Antibody,FITC |
|||
| CABT-47094MR | Creative Diagnostics | 0.1 mg | 651.6 EUR |
Mouse Monoclonal Anti-Human CD147-FITC conjugate |
|||
| CD147F-100 | Alpha Diagnostics | 100 Tests | 562.8 EUR |
Mouse Monoclonal Anti-Human CD147-PE conjugate |
|||
| CD147P-100 | Alpha Diagnostics | 100 Tests | 562.8 EUR |
Mouse CD147 ELISA Kit |
|||
| EMC0241 | Abclonal | 96Tests | 625.2 EUR |
Anti-Hu CD147 Alexa Fluor488 |
|||
| A4-274-T025 | ExBio | 25 tests | 184.8 EUR |
Anti-Hu CD147 Alexa Fluor488 |
|||
| A4-274-T100 | ExBio | 100 tests | 322.8 EUR |
Anti-CD147/Emmprin/BSG Antibody |
|||
| A00248-1 | BosterBio | 100ug/vial | 400.8 EUR |
Anti-CD147 Rabbit Monoclonal Antibody |
|||
| M00248-1 | BosterBio | 100ug/vial | 476.4 EUR |
|
Description: Rabbit Monoclonal CD147 Antibody. Validated in IF, WB and tested in Human, Mouse, Rat. |
|||
Anti-CD147 Antibody (BSG/963) |
|||
| A1475-100 | Biovision | each | 574.8 EUR |
Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | 336 EUR |
Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | 336 EUR |
Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | 336 EUR |
Mouse Anti Human Cd147 Monoclonal Antibody,AZIDE FREE |
|||
| CABT-47078MH | Creative Diagnostics | 0.1 mg | 795.6 EUR |
Mouse Monoclonal Anti-Human CD147-PE-Cy5-conjugate |
|||
| CD147PC-100 | Alpha Diagnostics | 100 Tests | 562.8 EUR |
CD147 Antibody |
|||
| DF6462 | Affbiotech | 200ul | 420 EUR |
CD147 Antibody |
|||
| AF5221 | Affbiotech | 200ul | 420 EUR |
CD147 Antibody |
|||
| AF0428 | Affbiotech | 200ul | 420 EUR |
CD147 antibody |
|||
| 70R-31695 | Fitzgerald | 100 ug | 392.4 EUR |
|
Description: Rabbit polyclonal CD147 antibody |
|||
CD147 antibody |
|||
| 70R-51470 | Fitzgerald | 100 ul | 292.8 EUR |
|
Description: Purified Polyclonal CD147 antibody |
|||
CD147 Antibody |
|||
| 49372-100ul | SAB | 100ul | 399.6 EUR |
CD147 Antibody |
|||
| 49372-50ul | SAB | 50ul | 286.8 EUR |
CD147 antibody |
|||
| 70R-14065 | Fitzgerald | 100 ug | 386.4 EUR |
|
Description: Affinity purified Mouse polyclonal CD147 antibody |
|||
CD147 antibody |
|||
| 10R-CD147aHU | Fitzgerald | 100 ug | 484.8 EUR |
|
Description: Mouse monoclonal CD147 antibody |
|||
CD147 Antibody |
|||
| ABD3164 | Lifescience Market | 100 ug | 525.6 EUR |
CD147 Antibody |
|||
| ABF0428 | Lifescience Market | 100 ug | 525.6 EUR |
CD147 Antibody |
|||
| ABF5221 | Lifescience Market | 100 ug | 525.6 EUR |
CD147 Antibody |
|||
| R30601 | NSJ Bioreagents | 100 ug | 419 EUR |
CD147 Antibody |
|||
| R31660 | NSJ Bioreagents | 100 ug | 419 EUR |
Anti-Hu CD147 Purified Low Endotoxin |
|||
| 12-507-C100 | ExBio | 0.1 mg | 200.4 EUR |
Mouse CD147/EMMPRIN ELISA kit |
|||
| E03C0234-192T | BlueGene | 192 tests | 1524 EUR |
|
Description: A competitive ELISA for quantitative measurement of Mouse CD147/EMMPRIN in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Mouse CD147/EMMPRIN ELISA kit |
|||
| E03C0234-48 | BlueGene | 1 plate of 48 wells | 624 EUR |
|
Description: A competitive ELISA for quantitative measurement of Mouse CD147/EMMPRIN in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Mouse CD147/EMMPRIN ELISA kit |
|||
| E03C0234-96 | BlueGene | 1 plate of 96 wells | 822 EUR |
|
Description: A competitive ELISA for quantitative measurement of Mouse CD147/EMMPRIN in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Mouse CD147/EMMPRIN ELISA Kit |
|||
| EME0043 | Abclonal | 96Tests | 625.2 EUR |
CD147(CB43) Antibody |
|||
| BNCA0363-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against CD147(CB43), APC conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNCA0424-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against CD147(8D6), APC conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNCAP0363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNCAP0363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNCAP0424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNCAP0424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC610363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC610363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC610424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC610424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC680363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC680363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC680424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC680424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNCR0363-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against CD147(CB43), RPE conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNCR0424-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against CD147(8D6), RPE conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNUB0363-100 | Biotium | 100uL | 250.8 EUR |
|
Description: Primary antibody against CD147(CB43), Concentration: 0.2mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNUB0363-500 | Biotium | 500uL | 549.6 EUR |
|
Description: Primary antibody against CD147(CB43), Concentration: 0.2mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNUB0424-100 | Biotium | 100uL | 250.8 EUR |
|
Description: Primary antibody against CD147(8D6), Concentration: 0.2mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNUB0424-500 | Biotium | 500uL | 549.6 EUR |
|
Description: Primary antibody against CD147(8D6), Concentration: 0.2mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC430363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC430363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC430424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC430424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC470363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC470363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC470424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC470424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD147 Conjugated Antibody |
|||
| C49372 | SAB | 100ul | 476.4 EUR |
CD147 Blocking Peptide |
|||
| AF5221-BP | Affbiotech | 1mg | 234 EUR |
CD147 Blocking Peptide |
|||
| AF0428-BP | Affbiotech | 1mg | 234 EUR |
CD147(CB43) Antibody |
|||
| BNC400363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC400363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC400424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC400424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC880363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC880363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC880424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC880424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC810363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC810363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC810424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC810424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNCP0363-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against CD147(CB43), PerCP conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNCP0424-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against CD147(8D6), PerCP conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNUM0363-50 | Biotium | 50uL | 474 EUR |
|
Description: Primary antibody against CD147(CB43), 1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNUM0424-50 | Biotium | 50uL | 474 EUR |
|
Description: Primary antibody against CD147(8D6), 1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC050363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC050363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC050424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC050424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC700363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC700363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC700424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC700424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC800363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC800363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC800424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC800424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNCB0363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNCB0363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNCB0424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNCB0424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC940363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC940363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC940424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC940424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC550363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC550363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC550424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC550424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNCH0363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNCH0363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNCH0424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNCH0424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD147 antibody (PE) |
|||
| 61R-1311 | Fitzgerald | 50 ug | 249.6 EUR |
|
Description: Rat monoclonal CD147 antibody (PE) |
|||
CD147 antibody (biotin) |
|||
| 61R-CD147aHUBT | Fitzgerald | 100 ug | 495.6 EUR |
|
Description: Mouse monoclonal CD147 antibody (biotin) |
|||
CD147 antibody (PE) |
|||
| 61R-CD147aHUPE | Fitzgerald | 120 tests | 703.2 EUR |
|
Description: Mouse monoclonal CD147 antibody (PE) |
|||
Basigin (CD147) Antibody |
|||
| 20-abx133774 | Abbexa |
|
|
CD147 Antibody (FITC) |
|||
| abx133900-100Assays | Abbexa | 100 Assays | 526.8 EUR |
CD147 Antibody (FITC) |
|||
| abx133900-50Assays | Abbexa | 50 Assays | 410.4 EUR |
Basigin (CD147) Antibody |
|||
| 20-abx133902 | Abbexa |
|
|
Basigin (CD147) Antibody |
|||
| abx139069-01mg | Abbexa | 0.1 mg | 444 EUR |
Basigin (CD147) Antibody |
|||
| abx139070-01mg | Abbexa | 0.1 mg | 444 EUR |
Basigin (CD147) Antibody |
|||
| abx139071-01mg | Abbexa | 0.1 mg | 444 EUR |
CD147 Antibody (Biotin) |
|||
| abx139074-01mg | Abbexa | 0.1 mg | 510 EUR |
CD147 Antibody (FITC) |
|||
| abx139075-100tests | Abbexa | 100 tests | 510 EUR |
Basigin (CD147) Antibody |
|||
| 20-abx007567 | Abbexa |
|
|
Basigin (CD147) Antibody |
|||
| abx019020-100ug | Abbexa | 100 ug | 410.4 EUR |
CD147 Antibody (Biotin) |
|||
| abx021360-100ug | Abbexa | 100 ug | 661.2 EUR |
Basigin (CD147) Antibody |
|||
| abx021361-02mg | Abbexa | 0.2 mg | 1312.8 EUR |
Basigin (CD147) Antibody |
|||
| 20-abx013476 | Abbexa |
|
|
CD147 Blocking Peptide |
|||
| 20-abx061356 | Abbexa |
|
|
CD147 Blocking Peptide |
|||
| 20-abx062045 | Abbexa |
|
|
Basigin (CD147) Antibody |
|||
| abx200501-100ug | Abbexa | 100 ug | 393.6 EUR |
CD147 Antibody (FITC) |
|||
| abx200502-100tests | Abbexa | 100 tests | 477.6 EUR |
Basigin (CD147) Antibody |
|||
| abx231430-100ug | Abbexa | 100 ug | 577.2 EUR |
Basigin (CD147) Antibody |
|||
| abx414662-01mg | Abbexa | 0.1 mg | 910.8 EUR |
Basigin (CD147) Antibody |
|||
| abx415446-2ml | Abbexa | 2 ml | 727.2 EUR |
Basigin (CD147) Antibody |
|||
| abx413466-02mg | Abbexa | 0.2 mg | 678 EUR |
Basigin (CD147) Antibody |
|||
| abx413470-1mg | Abbexa | 1 mg | 994.8 EUR |
Basigin (CD147) Antibody |
|||
| abx413959-025mg | Abbexa | 0.25 mg | 678 EUR |
Basigin (CD147) Antibody |
|||
| abx413960-01mg | Abbexa | 0.1 mg | 526.8 EUR |
CD147(CB43) Antibody |
|||
| BNC040363-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF405S conjugate, Concentration: 0.1mg/mL |
|||
CD147(CB43) Antibody |
|||
| BNC040363-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(CB43), CF405S conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC040424-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF405S conjugate, Concentration: 0.1mg/mL |
|||
CD147(8D6) Antibody |
|||
| BNC040424-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(8D6), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Recombinant Mouse Basigin/CD147 (C-6His) |
|||
| CP80-10ug | Novoprotein | 10ug | 169.2 EUR |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
|||
Recombinant Mouse Basigin/CD147 (C-6His) |
|||
| CP80-1mg | Novoprotein | 1mg | 2008.8 EUR |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
|||
Recombinant Mouse Basigin/CD147 (C-6His) |
|||
| CP80-500ug | Novoprotein | 500ug | 1423.2 EUR |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
|||
Recombinant Mouse Basigin/CD147 (C-6His) |
|||
| CP80-50ug | Novoprotein | 50ug | 363.6 EUR |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
|||
Rat Monoclonal Anti-Mouse CD147, Biotin (Clone OX114) (rat IgG1) |
|||
| MCD147-B | Alpha Diagnostics | 100 tests | 562.8 EUR |
Rat Monoclonal Anti-Mouse CD147, FITC (Clone OX114) (rat IgG1) |
|||
| MCD147-F | Alpha Diagnostics | 50 Tests | 489.6 EUR |
Rat Monoclonal Anti-Mouse CD147, Purified (Clone OX114) (rat IgG1) |
|||
| MCD147-M | Alpha Diagnostics | 100 ug | 578.4 EUR |
Rat Monoclonal Anti-Mouse CD147, PE (Clone OX114) (rat IgG1) |
|||
| MCD147-PE | Alpha Diagnostics | 50 tests | 416.4 EUR |
Purified Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 11470000 | AAT Bioquest | 100 ug | 365 EUR |
APC Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701B0 | AAT Bioquest | 25 tests | 383 EUR |
APC Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701B1 | AAT Bioquest | 100 tests | 995 EUR |
APC Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701B2 | AAT Bioquest | 500 tests | 2984 EUR |
FITC Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701G0 | AAT Bioquest | 100 tests | 547 EUR |
FITC Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701G1 | AAT Bioquest | 500 tests | 2051 EUR |
TRITC Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701H0 | AAT Bioquest | 100 tests | 547 EUR |
TRITC Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701H1 | AAT Bioquest | 500 tests | 2051 EUR |
PacBlue Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701I0 | AAT Bioquest | 100 tests | 547 EUR |
PacBlue Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701I1 | AAT Bioquest | 500 tests | 2051 EUR |
PacOrange Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701J0 | AAT Bioquest | 100 tests | 547 EUR |
PacOrange Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701J1 | AAT Bioquest | 500 tests | 2051 EUR |
PE Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701K0 | AAT Bioquest | 25 tests | 383 EUR |
PE Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701K1 | AAT Bioquest | 100 tests | 995 EUR |
PE Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701K2 | AAT Bioquest | 500 tests | 2984 EUR |
PerCP Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701S0 | AAT Bioquest | 25 tests | 383 EUR |
PerCP Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701S1 | AAT Bioquest | 100 tests | 995 EUR |
PerCP Anti-human CD147 Antibody *MEM-M6/6* |
|||
| 114701S2 | AAT Bioquest | 500 tests | 2984 EUR |
CD147(BSG/963) Antibody |
|||
| BNCA0963-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against CD147(BSG/963), APC conjugate, Concentration: 0.1mg/mL |
|||
CD147(BSG/963) Antibody |
|||
| BNCAP0963-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(BSG/963), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD147(BSG/963) Antibody |
|||
| BNCAP0963-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(BSG/963), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD147 recombinant monoclonal antibody |
|||
| A5760 | Bimake | 100ul X 3 | 714 EUR |
|
Description: A recombinant monoclonal antibody from rabbit against human CD147 for WB, IHC,ELISA |
|||
CD147(BSG/963) Antibody |
|||
| BNC610963-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against CD147(BSG/963), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD147(BSG/963) Antibody |
|||
| BNC610963-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against CD147(BSG/963), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD147(BSG/963) Antibody |
|||
| BNUM0963-50 | Biotium | 50uL | 474 EUR |
|
Description: Primary antibody against CD147(BSG/963), 1mg/mL |
|||
CD147(BSG/963) Antibody |
|||
| BNCR0963-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against CD147(BSG/963), RPE conjugate, Concentration: 0.1mg/mL |
|||
Susceptibility testing and molecular analyses revealed lowering GAS macrolide resistance charges, which can be attributed to the discount within the consumption of macrolides and/or the diminished circulation of macrolide-resistant clones lately. Such knowledge might present beneficial baseline data in focusing on therapeutic intervention and the formulation of type-specific GAS vaccines.